Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia.

PubWeight™: 0.80‹?›

🔗 View Article (PMID 27581216)

Published in Neurology on August 31, 2016

Authors

Jonathan D Rohrer1, Ione O C Woollacott2, Katrina M Dick2, Emilie Brotherhood2, Elizabeth Gordon2, Alexander Fellows2, Jamie Toombs2, Ronald Druyeh2, M Jorge Cardoso2, Sebastien Ourselin2, Jennifer M Nicholas2, Niklas Norgren2, Simon Mead2, Ulf Andreasson2, Kaj Blennow2, Jonathan M Schott2, Nick C Fox2, Jason D Warren2, Henrik Zetterberg2

Author Affiliations

1: From the Dementia Research Centre (J.D.R., I.O.C.W., K.M.D., E.B., E.G., A.F., M.J.C., S.O., J.M.N., J.M.S., N.C.F., J.D.W.), MRC Prion Unit (S.M., R.D.), Department of Neurodegenerative Disease, and Department of Molecular Neuroscience (J.T., H.Z.), UCL Institute of Neurology, Queen Square; Centre for Medical Image Computing (J.M.C., S.O.), University College London; Department of Medical Statistics (J.M.N.), London School of Hygiene and Tropical Medicine, UK; UmanDiagnostics (N.N.), Umeå; and Clinical Neurochemistry Laboratory (U.A., K.B., H.Z.), Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. j.rohrer@ucl.ac.uk.
2: From the Dementia Research Centre (J.D.R., I.O.C.W., K.M.D., E.B., E.G., A.F., M.J.C., S.O., J.M.N., J.M.S., N.C.F., J.D.W.), MRC Prion Unit (S.M., R.D.), Department of Neurodegenerative Disease, and Department of Molecular Neuroscience (J.T., H.Z.), UCL Institute of Neurology, Queen Square; Centre for Medical Image Computing (J.M.C., S.O.), University College London; Department of Medical Statistics (J.M.N.), London School of Hygiene and Tropical Medicine, UK; UmanDiagnostics (N.N.), Umeå; and Clinical Neurochemistry Laboratory (U.A., K.B., H.Z.), Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.

Articles cited by this

"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res (1975) 301.74

Classification of primary progressive aphasia and its variants. Neurology (2011) 11.82

Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain (2011) 9.90

Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol (2010) 4.04

The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans Med Imaging (1997) 3.94

Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2009) 2.76

Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain (2012) 2.65

Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Comput Methods Programs Biomed (1997) 2.56

Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry (2010) 2.44

Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol (2015) 2.00

Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain (2008) 1.82

Testing for nominal dysphasia. J Neurol Neurosurg Psychiatry (1980) 1.69

Arithmetic skills in patients with unilateral cerebral lesions. Cortex (1986) 1.63

Clinical staging and disease progression in frontotemporal dementia. Neurology (2010) 1.44

Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology (2015) 1.21

Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol (2005) 1.16

Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol (2014) 1.15

Clinical review. Frontotemporal dementia. BMJ (2013) 1.13

Neurofilament protein levels in CSF are increased in dementia. Neurology (1999) 1.11

Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol (2012) 1.09

Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology (2000) 1.07

Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. J Neurol Neurosurg Psychiatry (2014) 1.05

Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia. BMC Neurol (2013) 1.04

Geodesic Information Flows: Spatially-Variant Graphs and Their Application to Segmentation and Fusion. IEEE Trans Med Imaging (2015) 1.03

Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med (2016) 0.99

CSF neurofilament proteins in the differential diagnosis of dementia. J Neurol Neurosurg Psychiatry (2007) 0.97

CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls. Dement Geriatr Cogn Disord (2007) 0.97

A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia. Neurodegener Dis (2007) 0.95

The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer's disease. Dement Geriatr Cogn Disord (2006) 0.92

Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J Neurol Neurosurg Psychiatry (2015) 0.86

Comparative Assessment of the Prognostic Value of Biomarkers in Traumatic Brain Injury Reveals an Independent Role for Serum Levels of Neurofilament Light. PLoS One (2015) 0.85

Biomarkers in frontotemporal dementia. Biomark Med (2014) 0.77